Protective effects of thymidine, 5-aminoimidazolecarboxamide, and riboflavin against fetal abnormalities produced in rats by 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide.
D000014:Abnormalities, Drug-Induced / Q000517:prevention & control*; D000577:Amides / Q000627:therapeutic use; D000818:Animals; D001921:Brain / Q000002:abnormalities; D003545:Cysteine / Q000008:administration & dosage / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D005333:Fetus / Q000187:drug effects; D005865:Gestational Age; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007569:Jaw Abnormalities / Q000139:chemically induced; D017880:Limb Deformities, Congenital; D008334:Mandible / Q000002:abnormalities; D008431:Maternal-Fetal Exchange; D009056:Mouth Abnormalities / Q000139:chemically induced; D009602:Nitrosamines / Q000494:pharmacology / Q000633:toxicity; D010159:Palate / Q000002:abnormalities; D011247:Pregnancy; D051381:Rats; D012256:Riboflavin / Q000008:administration & dosage / Q000627:therapeutic use*; D013936:Thymidine / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D014226:Triazenes
D000577:Amides; D007093:Imidazoles; D009602:Nitrosamines; D014226:Triazenes; D003545:Cysteine; D012256:Riboflavin; D013936:Thymidine